Android app on Google Play

Amarin (AMRN) Surges Following Statistically Significant Study of AMR101

April 18, 2011 7:43 AM EDT Send to a Friend
Shares of Amarin Corporation plc (Nasdaq: AMRN) are jumping 70 percent higher this morning after the company announced statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

Amarin said triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the predefined non-inferiority b.

Link to full release.

You May Also Be Interested In

Related Categories

FDA, Hot FDA News, Momentum Movers

Add Your Comment